When most people start researching stem cell therapy in Colombia, the first questions they have are not about cell counts or delivery methods. They are about trust. Is this legal? Who is making sure the clinics are doing this safely? Is there anyone actually watching?
The answer is yes — and that agency is INVIMA.
Understanding what INVIMA does, what it requires, and where its authority currently ends is one of the most useful things you can do before choosing a clinic. This article breaks it down plainly, without the legal jargon.
What Is INVIMA?
INVIMA stands for Instituto Nacional de Vigilancia de Medicamentos y Alimentos, which translates to the National Institute for Food and Drug Surveillance. It is Colombia’s federal regulatory body for foods, drugs, pharmaceutical products, biological products, and medical devices. In terms of function and purpose, it is the closest equivalent to the United States FDA.
INVIMA operates under the authority of Colombia’s Ministry of Health and Social Protection, which is the broader government body responsible for national health policy. The Ministry sets the direction; INVIMA enforces the standards. This is a similar structure to how the US Department of Health and Human Services oversees the FDA.
For patients considering stem cell therapy in Colombia, INVIMA is the agency that matters most. It is the body responsible for licensing laboratories, overseeing tissue banking, and setting the quality standards that reputable clinics are expected to meet.
The Regulations That Actually Apply to Stem Cell Therapy
Colombia’s regulatory framework for cell and tissue therapies is built primarily on two documents: Decree 2493 of 2004 and Resolution 5108 of 2005.
Decree 2493 is the foundation. It governs how human cells and tissues are collected, processed, stored, transported, and disposed of. It applies to material from both living and deceased donors, and it covers the full chain of custody from the moment a donation is made to the moment cells are used in treatment. Resolution 5108 extended this framework to cover bone marrow and tissue banking operations specifically.
At the laboratory level, these regulations require something that not every country mandates. Every cell or tissue donor must be screened for a specific panel of infectious diseases before their material can be used. That panel includes syphilis, hepatitis B and C, HTLV I/II, HIV 1/2, Trypanosoma cruzi (the parasite that causes Chagas disease), cytomegalovirus, and Epstein-Barr virus. These are not optional tests. They are required by law for any INVIMA-compliant operation.
Labs must also operate under Good Manufacturing Practices, commonly referred to as GMP. GMP standards govern everything from the physical cleanliness of a facility to the documentation and traceability requirements for every batch of cells produced. A lab that is GMP-certified has been independently verified to meet these standards.
Under current Colombian law, the therapies that are explicitly approved include hematopoietic stem cell transplants performed at licensed transplant centers, and same-day autologous treatments where a patient’s own cells are collected and re-administered without substantial manipulation. Everything else — including cultured and expanded mesenchymal stem cell (MSC) therapies — exists in a more complicated regulatory space, which we will get into shortly.
The Regulatory Gap That Made Colombia a Global Hub
This is the part that most articles gloss over, but it is arguably the most important thing to understand about Colombia’s position in regenerative medicine.
Decree 2493 and Resolution 5108 are thorough in regulating how cells are processed and stored. What they do not do is classify expanded MSC infusions as a licensed drug or clinical procedure requiring individual product approval before use. This is a structural gap in the law, not a loophole that clinics are exploiting.
The practical effect of this gap is significant. Because INVIMA permits GMP-certified labs to culture and expand mesenchymal stem cells without requiring product-level approval for each therapy, Colombian clinics can offer something that is effectively unavailable in the United States through commercial channels.
In the US, the FDA requires that cell therapies meet a “minimal manipulation” standard to avoid being classified as a biologic drug requiring full approval. For most commercial MSC treatments, this means cells cannot be significantly processed or expanded outside the body. A typical bedside procedure under those restrictions might yield somewhere between 1 and 5 million cells.
In Colombia, a GMP-certified lab working within INVIMA’s framework can culture and expand those same cells over several weeks, producing concentrations of 50 to 200 million cells or more. That difference in cell count is not trivial. It is one of the primary reasons that patients who have researched this extensively end up in Bogota or Medellin rather than a US clinic.
This is not Colombia cutting corners. It is Colombia having a different regulatory framework — one that permits more at the processing stage while still requiring rigorous lab standards. The distinction matters when you are evaluating whether a Colombian clinic is operating legitimately.
What an INVIMA License Actually Covers
When a clinic or laboratory holds an INVIMA registration, it means the agency has verified that their operation meets specific standards. For regenerative medicine facilities, that generally includes the ethical sourcing of biological materials — meaning umbilical cord tissue, for example, must be collected under documented donor consent protocols. It includes GMP-compliant laboratory operations for cell expansion and cryogenic storage. It includes characterization requirements, meaning labs must be able to identify and verify what type of cells they are producing.
One of the most patient-facing aspects of INVIMA compliance is the Certificate of Analysis, or COA. A COA is a batch-specific document that details the exact cells used in a patient’s treatment. It should include the cell type, the total cell count, the viability percentage (how many cells in the batch are alive and functional), and the results of sterility testing. At Stem Cells Colombia, we consistently recommend that international patients ask any clinic they are considering to show them a sample COA before committing to treatment. A clinic that cannot produce one is a clinic worth being cautious about.
What INVIMA Does Not Currently Regulate
Being accurate about this is just as important as explaining what INVIMA does cover.
INVIMA does not evaluate the clinical efficacy of specific stem cell therapy protocols. It does not review whether a given treatment actually works for a particular condition. That kind of product-level clinical oversight — the type the FDA applies when reviewing a new biologic drug application — does not exist in Colombia for MSC therapies. INVIMA regulates how cells are made. It does not certify that a treatment will produce the outcomes a clinic describes.
The Colombian Ministry of Health has stated that any stem cell therapy lacking INVIMA approval or proven efficacy should only be offered as part of a formally authorized clinical trial with ethics committee oversight. That is the official policy position. The reality is that enforcement of this standard across all clinics in Colombia is uneven. Not every facility operating in the country is INVIMA-registered, and INVIMA’s capacity for ongoing market surveillance is limited compared to a body like the FDA.
This is why INVIMA registration should be treated as a necessary minimum, not a complete guarantee. It tells you the clinic is operating within a legitimate framework. It does not tell you the treatment will work, that the doctor is qualified, or that the specific protocol being offered is appropriate for your condition.
Embryonic stem cells occupy a separate category. Colombia does not authorize embryonic stem cells for clinical treatment. Their use is restricted to approved research under strict ethical oversight. Any clinic claiming to offer embryonic stem cell treatments to patients is operating outside the law.
INVIMA vs. the FDA: The Key Differences
Patients coming from the United States or Canada often want a direct comparison, so here is a plain-language version.
The FDA requires that any cell therapy intended for commercial use either qualify as a minimally manipulated product under specific exemptions, or go through a full Biologics License Application process, which takes years and costs tens of millions of dollars. This system produces rigorous data but also means that most advanced cell therapies never make it to patients outside of clinical trials.
INVIMA requires that cell processing labs meet GMP standards and that donor materials pass infectious disease screening. It does not require product-level approval for expanded MSC therapies, which means those therapies can reach patients without a years-long approval process. The tradeoff is that there is less clinical outcome data formally attached to each treatment.
Both bodies require ethics committee oversight for clinical trials, and both follow international Good Clinical Practice (GCP) standards in that context. The meaningful difference is at the commercial therapy level, and that difference is what makes Colombia accessible for patients who cannot wait for US regulatory timelines.
What This Means When You Are Choosing a Clinic
Knowing that INVIMA exists and that Colombia has a regulatory framework is one thing. Knowing how to use that information when evaluating specific clinics is another.
Start with registration. A legitimate clinic should be able to tell you directly that they hold INVIMA registration and that their laboratory partner is GMP-certified. If they cannot give you specific answers to those questions, that is a problem.
Ask about their lab. The best clinics either operate their own certified laboratory or work with a dedicated biotech lab that holds GMP and ISO certifications. The lab is where cell quality is determined, and a Certificate of Analysis from that lab should be available for every treatment batch.
Understand that JCI hospital accreditation, while a real and meaningful credential, is not the same thing as INVIMA registration for regenerative medicine. JCI accreditation evaluates hospital operations and management. It does not assess stem cell protocols or validate the quality of a clinic’s cell products. These are separate certifications with separate scopes.
Finally, be cautious of any clinic that is vague about what happens between when your cells are processed and when they are administered to you. A well-run, INVIMA-compliant clinic has documentation for every step of that process.
Where Colombian Regulation Is Heading
In 2024, a proposed piece of legislation was put forward in Colombia that would create a formal regulatory framework for “terapias avanzadas,” or advanced therapies. If passed, this law would establish defined approval pathways for expanded cell therapies, bringing them into a more structured regulatory category rather than leaving them in the current gap between tissue banking law and clinical procedure regulation.
This kind of legislation is likely to raise the compliance bar across the industry. Some smaller or less rigorous operations would probably not survive it. For patients, stronger formal regulation would mean more consistent protections and more transparency — at the potential cost of higher prices and reduced availability as the industry adjusts.
What this proposed legislation signals is that Colombia’s regulatory intent has been consistent: the goal is to build a framework around these therapies, not to shut them down. That trajectory is meaningful for anyone considering Colombia as a long-term option for regenerative care.
What You Should Take Away From This
INVIMA is a real agency with real standards. It is not a formality or a rubber stamp, and a clinic that holds INVIMA registration has met documented requirements for how its lab operates, how donor materials are screened, and how cell products are handled.
The most important thing to understand is what INVIMA does and does not cover. It rigorously governs process quality — lab standards, donor testing, GMP compliance, documentation. It does not evaluate clinical outcomes or certify that a specific treatment will work for your condition. That distinction matters, and any honest clinic will tell you the same thing.
Colombia’s regulatory environment for expanded MSC stem cell therapies is more permissive than what exists in the United States or most of Western Europe. But permissive with genuine standards is a very different thing from unregulated. Knowing the difference — and knowing what questions to ask when you contact Stem Cells Colombia or another clinic — puts you in a much stronger position to make a decision you feel confident about.